A study analysing CTLA-4 Expression in Tumor-infiltrating Lymphocytes Is Irrelevant to PD-L1 Expression in NSCLC
Latest Information Update: 06 Dec 2021
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Pharmacodynamics
- 06 Dec 2021 New trial record
- 01 Dec 2021 Results published in the Anticancer Research